Oncology Adjuvants Market Overview

The global oncology adjuvants market was valued at around US$ 506.01 Million at the end of 2021. The market is projected to register a 4.60% CAGR and top a valuation of US$ 829.86 Million by 2032.

The increasing prevalence of cancers cases across the globe is the primary factor responsible for the markets growth.

Oncology adjuvant therapy is a type of cancer therapy that includes cancer treatment after the primary therapy is completed. The fundamental goal of oncology adjuvant therapy is to lower the risk of cancer recurrence. Chemotherapy, targeted therapy, radiation therapy, hormone therapy, or biological therapy are all examples of oncology adjuvant therapy. Before choosing an appropriate adjuvant therapy, oncologists take into account a number of elements, such as statistical data.

The primary goal of oncology adjuvant therapy is to eliminate the danger of cancer recurrence in order to increase the odds of survival for cancer patients. Through oncological surgery and adjuvant therapy, oncology adjuvant therapy is utilized to treat numerous cancers, including kidney carcinoma and some types of brain cancer. These tumours can also include colon, lung, breast, prostate, and other gynaecological malignancies.

Attributes Details
Oncology Adjuvants Market Value in 2021 US$ 506.01 Million
Oncology Adjuvants Market Value in 2032 US$ 829.86 Million
Oncology Adjuvants Market CAGR (2022 to 2032) 4.60%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

What are the Major Drivers Boosting the Demand for Oncology Adjuvants Market?

The market for oncology adjuvants is supposed to drive due to increasing prevalence of cancer which ultimately surge demand for cancer hospitals. Cancer treatment centres frequently employed the procedure to raise the efficiency of initial care and hence enhance patient outcomes. Additionally, it is anticipated that an increase in cancer incidence and funding for cancer research will fuel market expansion.

Moreover, changing lifestyles and increasing in habits such as smoking, unhealthy diet, physical inactivity, and others are also supposed to increase the risk of cancer, boosting the market’s growth. For instance, in 2018, according to
International Agency For Research on Cancer (IARC), about 17.0 million new cancer cases were found globally, and around 9.5 million cancer death. Also, the predicted that the global burden of cancer is anticipated to grow about 27.5 million by 2040.

Which Region Shows Strong Growth Potential in the Oncology Adjuvants Market?

The oncology adjuvants market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.

North America dominated the regional oncology adjuvant market due to the presence of numerous cancer research centres in the region. Additionally, market expansion in this region is anticipated to be aided by the rising incidence of cancer. Also, it is anticipated that enhanced R&D efforts to provide cutting-edge cancer treatments will support market expansion in the region.

Moreover, Asia Pacific is supposed to grow fastest over the forecast duration due to an increase in per capita healthcare spending for higher quality. Growing R&D initiatives and a rise in cancer treatment demand in the area are anticipated to expand market opportunities. In addition, the region's expanding number of cancer hospitals and the increasing acceptance of new technology both contribute to the market's expansion.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Who are the Key Manufacturers in the Oncology Adjuvants Market?

Eli Lilly, Amgen, BMS, Biogen, Sanofi, AstraZeneca, Pfizer, Hengrui Medicine, Hisun Pharmaceutical, Yibai Pharmaceutical, SL Pharmaceutical, Zhendong Pharmaceutical, Main Luck Pharmaceuticals, Sanjiu Medical, and Livzon Pharmaceutical

Scope of Report

Report Attributes Details
Growth Rate CAGR of 4.60% 2022 to 2032
Base Year for Estimation 2021
Historical Data 2012 to 2021
Forecast Period 2022 to 2032
Qualitative Units Revenue in USD Million, Volume in Units, and CAGR from 2022 to 2032
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segment Covered Application, Indication, End-User, Region
Region Covered North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa
Key Countries Profiled USA, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Malaysia, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, North Africa, Turkey, Israel
Key Players Eli Lilly; Amgen; BMS; Biogen; Sanofi; AstraZeneca; Pfizer; Hengrui Medicine; Hisun Pharmaceutical; Yibai Pharmaceutical; SL Pharmaceutical; Zhendong Pharmaceutical; Main Luck Pharmaceuticals; Sanjiu Medical; Livzon Pharmaceutical
Customization Available Upon Request

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Key Segments Covered in the Oncology Adjuvants Market Survey

By Application:

  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Hormone Therapy
  • Targeted Therapy
  • Others

By Indication:

  • Sarcoma
  • Breast Cancer
  • Colorectal Cancer
  • Glioblastoma
  • Prostate Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Others

By End-user:

  • Cancer research Institute
  • Cancer Hospitals

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

What is the Growth Outlook for the Global Oncology Adjuvants Market?

The global oncology adjuvants market is anticipated to register a CAGR of 4.60% during the forecast period.

Who are the Prominent Players in the Oncology Adjuvants Market?

Eli Lilly, Amgen, BMS, Biogen, Sanofi, AstraZeneca, Pfizer, Hengrui Medicine, Hisun Pharmaceutical, Yibai Pharmaceutical, SL Pharmaceutical, Zhendong Pharmaceutical, Main Luck Pharmaceuticals, Sanjiu Medical, and Livzon Pharmaceutical, among others are some prominent oncology adjuvants market players.

Recommendations

Healthcare

Oncology Information Systems Market

July 2022

REP-GB-15150

August 2023

333 pages

Healthcare

Oncology Imaging Software Market

September 2024

REP-GB-12102

Upcoming

Healthcare

Oncology Apoptosis Modulators Market

September 2024

REP-GB-1435

Upcoming

Healthcare

Oncology Blood Testing Market

March 2018

REP-GB-6449

July 2022

342 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Oncology Adjuvants Market

Schedule a Call